Oncolytic plasmid: A novel strategy for tumor immuno-gene therapy

Oncology Letters

Volumn 3, Issue 2, 2012, Pages 387-390

  Yoshihara, Chieko ^a   Hamada, Katsuyuki ^b   Kuroda, Minako ^a   Koyama, Yoshiyuki ^a  

^a OTSUMA WOMEN'S UNIVERSITY   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenovirus death protein; Gene therapy; Immunotherapy; Plasmid; Tumor

Indexed keywords

ADENOVIRUS DEATH PROTEIN; ADENOVIRUS PROTEIN; CHONDROITIN SULFATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC VIRUS; PLASMID DNA; PLASMID DNA ADENOVIRUS DEATH PROTEIN; POLYETHYLENEIMINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOGENETICS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PLASMID; TUMOR GROWTH;

EID: 84855249252     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.467     Document Type: Article

References (18)

1. De Pace NG: Sulla scomparsa di un enorme cancro vegetante del collo dell'utero senza cura chirurgica. Ginecologia 9: 82-88, 1912.
2. Martuza RL, Malick A, Markert JM, Ruffner KL and Coen DM: Experimental therapy of human glioma by means of a mutant. Science 252: 854-856, 1991.
3. Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB and Martuza RL: Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 10: 2741-2755, 1999.
4. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA and Errington F: Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 8: 1581-1588, 2008.
5. Suzuki K, Alemany R, Yamamoto M and Curiel DT: The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 8: 3348-3359, 2002.
6. Wold WSM, Cladaras C, Magie SC and Yacoub N: Mapping a new gene that encodes an 11,600-molecular-weight protein in the E3 transcription unit of adenovirus 2. J Virol 52: 307-313, 1984.
7. Tollefson AE, Ryerse JS, Scaria A, Hermiston TW and Wold WS: The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 220: 152-162, 1996.
8. Wold WSM, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL and Tollefson AE: Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol 11: 380-386, 1999.
9. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ and Wold WS: The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 70: 2296-2306, 1996.
10. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE and Wold WS: Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 74: 6147-6155, 2000.
11. Ito T, Yoshihara C, Hamada K and Koyama Y: DNA/polyethyleneimine/hyaluronic acid small complex particles and tumor suppression in mice. Biomaterials 31: 2912-2918, 2010.
12. Lavoie JN, Nguyen M, Marcellus RC, Branton PE and Shore GC: E4orf4, a novel adenovirus death factor that induces p53- independent apoptosis by a pathway that is not inhibited by zVADfmk. J Cell Biol 140: 637-645, 1998.
13. Malhotra S, Kim T, Zager J, Bennett J, Ebright M, D'Angelica M and Fong Y: Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery 141: 520-529, 2007.
14. Hamada K, Desaki J, Nakagawa K, Zhang T, Shirakawa T, Gotoh A and Tagawa M: Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther 15: 1121-1128, 2007.
15. Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB and Martuza RL: Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 10: 2741-2755, 1999.
16. Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ and Houghton AN: Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Investig 102: 1258-1264, 1998.
17. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN and Wolchok JD: Clin Cancer Res 9: 1284-1290, 2003.
18. Tang DC, DeVit M and Johnston SA: Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152-154, 1992.